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Abstract
Aims/hypothesis The teratogenic consequences of angiotensin-
converting enzyme inhibitors angiotensin receptor blockers
(ARBs) during the second and third trimesters of pregnancy
are well described. However, the consequences of exposure
during the first trimester are unclear, especially in diabetes.
We report the experience from DIRECT (DIabetic REti-
nopathy and Candesartan Trials), three placebo-controlled
studies designed to examine the effects of an ARB,
candesartan, on diabetic retinopathy.
Methods Over 4 years or longer, 178 normotensive women
with type 1 diabetes (86 randomised to candesartan, 32 mg
once daily, and 92 assigned to placebo) became pregnant
(total of 208 pregnancies).
Members of the Study Group are shown in the Electronic
supplementary material (ESM).
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Results More than half of patients were exposed to
candesartan or placebo prior to or in early pregnancy, but
all discontinued it at an estimated 8 weeks from the last
menstrual period. Full-term pregnancies (51 vs 50),
premature deliveries (21 vs 27), spontaneous miscarriages
(12 vs 15), elective terminations (15 vs 14) and other
outcomes (1 vs 2) were similar in the candesartan and
placebo groups. There were two stillbirths and two ‘sick
babies’ in the candesartan group, and one stillbirth, eight
‘sick babies’ and one cardiac malformation in the placebo
group.
Conclusions/interpretation The risk for fetal consequences
of ARBs in type 1 diabetes may not be high if exposure is
clearly limited to the first trimester. Long-term studies in
fertile women can be conducted with ARBs during
pregnancy, provided investigators diligently stop their
administration upon planning or detection of pregnancy.
Trial registration ClinicalTrials.gov DIRECT-Prevent 1
NCT00252733; DIRECT-Protect 1 NCT00252720; DIRECT-
Protect 2 NCT00252694.
Funding The study was funded jointly by AstraZeneca and
Takeda.
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Introduction
Agents that block the renin–angiotensin system (RAS),
angiotensin-converting enzyme inhibitors (ACEis) and
blockers of the angiotensin type-1 (AT1) receptor (ARBs),
are among the most utilised and effective antihypertensive
agents. In particular, RAS blockers are important for
patients with type 1 and 2 diabetes with hypertension and/
or microalbuminuria because they reduce progression of
diabetic renal damage [1]. However, both ACEis and ARBs
are known to cause fetal malformations and neonatal
problems if administered during pregnancy and this can
prove a deterrent to their use in women of child-bearing
potential [2, 3].
The teratogenic potential of RAS-inhibiting/blocking
agents administered during the second and third trimesters
of pregnancy is well established. Abnormalities reported
include fetal craniofacial abnormalities and limb contrac-
tures, probably consequent to oligohydramnious and failed
renal development [3]. However, whether there are similar
deleterious effects of exposure to ACEis or ARBs during
the first trimester remains controversial, with conflicting
reports of increased malformations, specifically cardiac
malformations, in infants of mothers exposed to ACEis,
as opposed to other antihypertensive agents, during the first
3 months of pregnancy [4–6]. The controversy is further
complicated because both hypertension [6, 7] and diabetes
[8] carry increased teratogenic potential per se, which
makes it difficult to discern the effects of either disease
from those of the drugs. In addition, previous studies [4, 5]
made a specific effort to exclude women who had diabetes
before pregnancy from their analyses. The absence of data
specific to diabetic women of child bearing age presents a
difficult dilemma. Should young diabetic women with
hypertension or early diabetic nephropathy be denied
treatment with RAS-inhibiting agents for fear of fetal
exposure in case of pregnancy? In addition, it is important
to include rather than exclude women of child-bearing
potential from clinical trials of these agents, so that the
results can be generalised to young diabetic patients of
both sexes.
DIRECT (DIabetic REtinopathy and Candesartan Trials)
[9, 10], a group of clinical studies designed to study the
effects of candesartan on diabetic retinopathy, offers a
unique opportunity to investigate the consequences of ARB
exposure during early pregnancy because: (1) women with
diabetes were randomised to treatment with either cande-
sartan or placebo for at least 4 years; (2) the study protocol
included careful instructions to stop the test drug whenever
pregnancy was either being contemplated or otherwise
diagnosed; and, (3) all women who became pregnant were
normotensive. As none of the women who became pregnant
took the study drug beyond the eighth week, the reports
collected are likely to reflect exposure during the early first
trimester only.
Methods
The design of the DIRECT programme has been reported
elsewhere [9, 10]. In brief, 1,421 patients with type 1
diabetes and no retinopathy at baseline (DIRECT-Prevent 1),
1,905 patients with type 1 diabetes and mild to moderately
severe non-proliferative retinopathy at baseline (DIRECT-
Protect 1) and 1.905 patients with type 2 diabetes and mild to
moderately severe non-proliferative retinopathy (DIRECT-
Protect 2) were randomised to either candesartan, 32 mg once
daily, or placebo. All patients were normoalbuminuric
(albumin excretion rate <20 μg/min) at baseline. Type 1
patients were all normotensive (BP≤130/85 mmHg) and type
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2 patients were either normotensive, or mildly hypertensive
(BP≤160/90 mmHg) and treated with agents other than RAS
inhibitors. All subjects gave their informed consent. The study
protocol was approved by the responsible ethics committee in
each participating centre and carried out in accordance with
the Declaration of Helsinki as revised in 2000.
Women of child-bearing potential were advised to
practice effective contraception. Investigators were
instructed to halt study drug on first knowledge of
pregnancy or if a woman was planning pregnancy, to report
the instance with use of a specific pregnancy report form,
and later to report the outcome of pregnancy on a
pregnancy outcome form. Where required by local regu-
lations and/or the protocol, the investigators also reported
pregnancy outcome-related adverse events. The pregnancy
report form included the dates of the last menstrual period,
expected date of delivery and last dose of study drug.
Pregnancy outcome forms included data on delivery (date,
pre-term or full, medical or spontaneous termination) and
child status (healthy, sick, congenital malformation, still-
born). Premature birth was defined as birth less than
37 weeks from the last menstrual period. A description of
diseases in the infants was not requested by the form. The
DIRECT database included data on baseline clinical
variables, such as BMI, BP, HbA1c and creatinine. Finally,
the dates of re-entry into the study after end of pregnancy
and/or lactation were recorded. The data from the pregnan-
cy report and pregnancy outcome forms of women who
received at least one dose of the study drug were compiled
and aligned with data from the studies, including adverse
event reports. Alignment between data was established
through use of calendar dates, as the pregnancies occurred
without relation to scheduled protocol assessments.
Estimates of the interval between study entry and
beginning of pregnancy were based on the assessed last
menstrual period.
Results
Overall, 615 (43.3%), 813 (42.7%) and 957 (50.2%)
women were randomised to DIRECT-Prevent 1, DIRECT-
Protect 1 and DIRECT-Protect 2, respectively. Of the
women who were randomised and took at least one dose
of study drug, 178 patients (73 from Prevent 1 and 105
from Protect 1) became pregnant (86 from the candesartan
and 92 from the placebo groups) (Fig. 1). These 178
patients had a total of 208 pregnancies (12 patients in the
candesartan and 12 in the placebo group had more than one
pregnancy). No pregnancies occurred in DIRECT-Protect 2
(mean age 57.9 years). The baseline characteristics of
women in DIRECT-Prevent 1 and DIRECT-Protect 1 are
shown in Table 1. The majority of patients were white.
Compared with those who did not become pregnant,
women who did were younger and tended to have shorter
durations of diabetes, but were otherwise similar. Patient
characteristics were also similar in the candesartan and
placebo groups.
Considering the first pregnancy during the study in each
woman who became pregnant, 14 women taking candesar-
tan and 16 taking placebo discontinued the study drug well
in advance of the last menstrual period (more than 8 weeks
before); 18 women taking candesartan and 13 taking
placebo discontinued the drug 8 to 0 weeks prior to last
menstrual period; 42 women taking candesartan and 45
taking placebo discontinued 0 to 8 weeks after their last
menstrual period. In 30 women the interval between the last
dose and last menstrual period could not be numerically
calculated, but all patients were known to have discon-
tinued candesartan treatment before the end of the first
trimester. Accordingly, over half the patients were likely to
have been exposed to study drug during trimester 1.
Evaluation of all subsequent pregnancies showed that
candesartan treatment was either stopped before the end
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of the first trimester or was never resumed after the
preceding pregnancy.
Delivery outcomes were similar for the candesartan and
placebo groups: full-term delivery (51 candesartan, 50
placebo), premature birth (21 candesartan, 27 placebo),
spontaneous miscarriage (12 candesartan, 15 placebo),
elective termination (15 candesartan, 14 placebo), other
(one candesartan, two placebo). Most infants were healthy,
whether full term or premature. There were two stillbirths
in the candesartan group and one in the placebo group, two
‘sick babies’ in the candesartan group and eight in the
placebo group. The only congenital malformation reported
was a ventricular septal defect in the placebo group.
No geographic pattern appeared for distribution of
pregnancies, with different frequencies of pregnancies
across countries being accounted for by the numbers of
patients included in DIRECT-Prevent 1 and DIRECT-
Protect 1 in the different countries. A total of 69 patients
restarted the study drug and the median time between last
menstrual period and resumption of study drug was
406 days for the candesartan and 456 days for the placebo
patients. The time to re-entry into the studies varied
considerably, depending on any period of lactation in
addition to pregnancy, because candesartan is contraindi-
cated during lactation. Pregnancies not going full term were
associated with the women rapidly resuming study drug.
Discussion
The DIRECT experience indicates that exposure to a
relatively high dosage of candesartan, 32 mg/day, for up
to 8 weeks into the first trimester of pregnancy may not
result in a higher rate of malformations than placebo in
normotensive normoalbuminuric women with type 1
diabetes. Only one instance of cardiac malformation was
reported in the study and it occurred in a woman
administered placebo, taking no antihypertensive drugs
and using only insulin as a glucose-lowering agent.
While the fetal consequences of RAS-inhibiting drugs
seem to result primarily from exposure during the second
and third trimesters, to date there have been insufficient
data to exclude similar detrimental effects of exposure
during the first trimester. In a cohort study of 29,507 infants
born in Tennessee, USA, Cooper et al. [4] reported that 202
infants exposed to an ACEi during the first trimester had an
Table 1 Baseline characteristics of women in DIRECT-Prevent 1 and DIRECT-Protect 1
Variable DIRECT–Prevent 1 (n=615) DIRECT–Protect 1 (n=813)
Candesartan (n=297) Placebo (n=318) Candesartan (n=413) Placebo (n=400)
n (%)
Pregnancy 33 (11.1) 40 (12.6) 53 (12.8) 52 (13.0)
No pregnancy 264 (88.9) 278 (87.4) 360 (87.2) 348 (87.0)
Age at inclusion (years)
Pregnancy 26±5 (19–36) 26±5 (18–40) 26±5 (18–38) 26±5 (19–43)
No pregnancy 31±8 (18–50) 31±9 (18–52) 32±9 (5.4–13.7) 33±9 (18–55)
Duration of diabetes (years)
Pregnancy 5.8±3.7 6.3±4.0 11.3±4.0 11.4±3.9
No pregnancy 7.2±4.0 7.0±3.8 11.1±4.3 11.9±3.7
Smokers (never/former/occasional/habitual)
Pregnancy 33 (23/2/3/5) 40 (32/0/2/6) 53 (43/4/3/3) 51 (44/2/3/2)
No pregnancy 264 (201/16/19/28) 278 (199/15/22/42) 360 (260/29/26/45) 348 (263/17/8/60)
HbA1c (%)
Pregnancy 8.1±1.4 (6.0–10.6) 8.8±2.2 (5.3–15.3) 8.4±1.6 (5.4–13.7) 8.4±1.5 (5.8–13.7)
No pregnancy 8.2±1.8 (4.8–17.9) 8.4±1.8 (4.8–15.9) 8.7±1.6 (5.4–15.6) 8.6±1.6 (4.8–15.6)
BMI (kg/m2)
Pregnancy 23±4 (18–34) 23±3 (18–32) 24±3 (19–33) 23±3 (16–31)
No pregnancy 24±4 (17–43) 24±4 (16–35) 24±4 (13–48) 25±4 (16–44)
Blood pressure (mmHg)
Pregnancy 110/70±7/7 (97–127)/(58–84) 110/70±10/7 (86–127)/(54–84) 113/73±10/6 (88–130)/(60–84) 113/73±9/6 (93–132)/(60–84)
No pregnancy 112/72±9/7 (86–133)/(50–90) 112/72±10/7 (77–130)/(50–91) 113/73±10/6 (77–166)/(53–96) 114/73±10/7 (93–132)/(53–97)
Creatinine (mmol/l)
Pregnancy 82.4±9.6 (65.0–106.8) 81.0±10.5 (57.3–104.9) 81.5±9.1 (60.2–107.8) 84.1±11.4 (66.0–111.7)
No pregnancy 82.5±11.4 (55.3–116.5) 82.0±11.7 (56.3–134.0) 82.2±11.2 (56.3–118.4) 82.5±10.3 (56.3–114.6)
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increased risk of malformations, specifically cardiac mal-
formations, compared with 209 infants whose mothers took
other antihypertensive agents during the first trimester. In a
Swedish cohort of 1,418 women who had taken antihyper-
tensives during the first trimester, Lennestål et al. [5] were
unable to find a different incidence of cardiac malforma-
tions between the infants of mothers who had taken an
ACEi and those who had used other agents, notably beta-
blockers. Caton et al. reported similar rates of use of any
antihypertensive medication, including RAS blockers, in
the mothers of 5,021 infants born with cardiac malforma-
tions and 4,796 controls without birth defects in a survey
across ten US states covering the years 1997–2003 [6].
The DIRECT experience is pertinent in this regard.
Although small compared with the above observational
studies, the clinical trial setting allowed for a fairly
precise estimation of drug exposure relative to concep-
tion date and for comparison with placebo. It is estimated
that the frequency of fetopathy from drug-related RAS
inhibition consequent to exposure during the second and
third trimesters is about 10–20% [11]. If the risk were of
similar magnitude in the first trimester, one would have
expected several cases to occur in the candesartan-treated
group.
Estimates of the interval between study drug discontin-
uation and beginning of pregnancy were based on the
assessed last menstrual period. Cross-matching of the
pregnancy report form and DIRECT database indicates that
no woman took the study drug after the eighth week of
pregnancy. Some uncertainty as to the precise date of
conception remains inevitable, even though the last men-
strual period is the accepted method for establishing it.
However, these data strongly suggest that there was
exposure to study drug during the first trimester in many
of the women taking candesartan, but in no case did such
exposure extend beyond the first trimester.
Overall, the incidence of cardiac malformations in
DIRECT was lower than those reported in previous
studies of hypertensive non-diabetic women [2–6]. This
suggests that hypertension per se might have played a
teratogenic role in those case series independently of the
agents used to treat it. Even taking into account the
potential teratogenic effect of diabetes and the fact that
HbA1c at enrolment and prior to last menstrual period
exceeded recommended targets [12], the number of adverse
pregnancy outcomes was fairly low in the DIRECT
experience.
It is important to note, however, that both receptor types
AT1 and AT2 are produced early in the human embryo
(24 days’ gestation) and all components of the RAS have
been demonstrated by 30–35 days of gestation [13],
suggesting a role for angiotensin II in early organogenesis.
In spite of explicit warning, women of fertile age continue
to be exposed to RAS-inhibiting/blocking agents through-
out pregnancy with unfortunate consequences [4–6, 14].
The treatment of hypertension and diabetic nephropathy in
non-pregnant women with type 1 diabetes mellitus is
clearly justified, at least until pregnancy is sought or
confirmed. However, in real life women may present much
later than the eighth week, even when planning pregnancy,
and may not seek medical advice early. Hence, the need to
be extremely careful when using RAS blockers in fertile
women.
The DIRECT experience supports the notion that
benefits vs risks of treating diabetic women of child-
bearing potential can be verified by including these patients
into clinical trials that assess the effects of RAS blockers. In
DIRECT there was little concern that the interruption in
study drug necessitated by pregnancy would influence the
overall study results as this situation applied to only a
fraction of the study population and most patients resumed
study drug at the conclusion of pregnancy/lactation.
In conclusion, the DIRECT clinical trial experience
indicates that: (1) the teratogenic risks of ARBs may be
small if exposure is clearly limited to early first trimester of
pregnancy; and (2) women of child-bearing age can take
RAS-inhibiting/blocking agents for valid reasons and still
avoid exposure during the vulnerable (teratogenic risk)
periods of pregnancy if both patients and prescribing
physicians are appropriately advised and provided they
will diligently stop the agent upon planning or detection of
pregnancy. However, longer surveys of fetal exposure to
RAS blockers are required to confirm that the risk is as low
as reported in DIRECT, and other trials in which pregnan-
cies occurred should report their outcomes in order that a
subsequent meta-analysis may be performed. Appropriately
dimensioned trials of antihypertensive and other therapies
during pregnancy might provide important information and
guidance for women with diabetes.
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